E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis
about
Candida albicans Biofilms and Human DiseaseEmerging drugs and vaccines for candidemiaCandida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsAll about that fat: Lipid modification of proteins in Cryptococcus neoformansNovel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation.Comparative Analysis of Protein Glycosylation Pathways in Humans and the Fungal Pathogen Candida albicans.Endoplasmic reticulum localized PerA is required for cell wall integrity, azole drug resistance, and virulence in Aspergillus fumigatus.Biosynthesis of GPI-anchored proteins: special emphasis on GPI lipid remodeling.The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicanscspA influences biofilm formation and drug resistance in pathogenic fungus Aspergillus fumigatusSynthesis and Biological Evaluation of Novel 2-Aminonicotinamide Derivatives as Antifungal Agents.Chemical Genomics-Based Antifungal Drug Discovery: Targeting Glycosylphosphatidylinositol (GPI) Precursor Biosynthesis.Bst1 is required for Candida albicans infecting host via facilitating cell wall anchorage of Glycosylphosphatidyl inositol anchored proteins.Combination antifungal therapy for invasive fungal infections in children and adults.Novel strategies against Candida biofilms: interest of synthetic compounds.Combination therapy for the treatment of pulmonary mold infections.Exploiting mitochondria as targets for the development of new antifungals.Central Role of the Trehalose Biosynthesis Pathway in the Pathogenesis of Human Fungal Infections: Opportunities and Challenges for Therapeutic Development.The anti-Aspergillus drug pipeline: Is the glass half full or empty?Diagnosis, classification, and therapeutic interventions for sinopulmonary Aspergillosis.The antifungal pipeline: a reality check.Drugs currently under investigation for the treatment of invasive candidiasis.Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi.Drugs in Clinical Development for Fungal Infections.Aspergillus fumigatus Cap59-like protein A is involved in α1,3-mannosylation of GPI-anchors.The top three areas of basic research on Aspergillus fumigatus in 2011.Chemogenomic profiling of the fungal pathogen Candida albicans.In vitro and in vivo Evaluation of the Antifungal Activity of APX001A/APX001 Against Candida auris.A new small-molecule KRE2 inhibitor against invasive Candida parapsilosis infection.New Horizons in Antifungal Therapy.In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model.Targeting the GPI biosynthetic pathway.Recent Advances in the Treatment of Scedosporiosis and Fusariosis.Significantly Improved Pharmacokinetics Enhances Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis
P2860
Q26778729-4FC9FF53-7BD7-47C6-941D-040676AF1970Q26828993-2DE77C88-E810-40CB-941A-603156293992Q26863344-C4FD5BF4-0451-44C5-8CB3-EC0F08C7DDEEQ28068079-4502AC97-487E-4FF4-9519-FFBC0B016AF2Q33636471-57FC55E2-0DF8-419D-B594-F39F2A15421DQ33930289-343A4D38-91C5-4505-807B-BBDB14E69E5FQ33956119-1CC6B25D-BA8B-49F4-A2E4-B0D36EF6BBD8Q34045400-50EC4F16-4BFD-46A2-940D-89EBE41B05FBQ34923233-C503E50F-524A-4BEC-A8C6-E4545712780BQ35188097-6A4DD3F6-2B82-4D5B-826D-8ACEEA6F5D2FQ36245326-F0363DD5-251B-4F98-AF03-86CBE66EC484Q36539252-D6313A05-DD2F-45DB-A8A5-6F52F4424A03Q37314985-438243DB-69EB-4275-82C1-A0C16616979CQ38102782-700456DA-E319-47EA-BA45-C404E96165B7Q38670904-594776B5-4597-40D8-B20C-E0AFE109B39DQ38806932-53B7CAF3-47A2-486F-9BDE-27E994C1689EQ38837358-745797FD-8CA3-4762-B57A-037472DD5A01Q38905119-AA1AA7DB-C522-4BAF-BE7D-EB0B19480765Q38937577-6980840B-8C53-4F4C-B709-341C9016D468Q39091924-DF22CBCE-DEAC-404C-B52F-2FB785CD5A08Q39299949-A355BAFB-291C-4101-967A-9311A3F77E60Q39375330-02FA8EE1-C7F5-4106-B2A5-0667AEF3C733Q40045666-74F712E7-BE71-4ADD-AA7D-28AE76947B61Q40070714-7BB328E5-58D3-41B0-96DC-80BAD7518910Q40540301-B1167B10-AE98-4ED9-B144-F0A3A2D9BD65Q44820840-603FDDF8-BAB0-481C-8D52-5C304E8B7473Q46248402-8F1B32BE-F579-46FE-808D-E516EFD30A80Q47195606-7785AC61-9B20-46D1-88DD-703D8C7F4D3FQ47702018-7CBEA1A8-23E9-4FF4-AC7C-4588E0D6CAD4Q48149179-CDAD6C4C-737C-4847-AE57-C45FBBC6CE1AQ49598880-C1E2388E-7FEA-47FA-986B-6541515FB394Q52683703-F7E34ECB-273E-4257-B1A9-1030E79F7EFFQ55453637-BC4BC3AB-F92E-447C-9E8C-AE83CD5AF817Q58701121-DEDBDCB7-F399-4E30-856D-B070EC3DB591
P2860
E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
E1210, a new broad-spectrum an ...... sphatidylinositol biosynthesis
@ast
E1210, a new broad-spectrum an ...... sphatidylinositol biosynthesis
@en
type
label
E1210, a new broad-spectrum an ...... sphatidylinositol biosynthesis
@ast
E1210, a new broad-spectrum an ...... sphatidylinositol biosynthesis
@en
prefLabel
E1210, a new broad-spectrum an ...... sphatidylinositol biosynthesis
@ast
E1210, a new broad-spectrum an ...... sphatidylinositol biosynthesis
@en
P2093
P2860
P356
P1476
E1210, a new broad-spectrum an ...... sphatidylinositol biosynthesis
@en
P2093
Kappei Tsukahara
Katsura Hata
Mamiko Miyazaki
Nao-Aki Watanabe
Takaaki Horii
P2860
P304
P356
10.1128/AAC.00731-11
P407
P50
P577
2011-12-05T00:00:00Z